4,155.00
+10(+0.24%)
Currency In JPY
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
1779
First IPO Date
January 01, 2001
| Name | Title | Pay | Year Born |
| Mr. Mutsuo Kanzawa | Chairman & Chief Executive Officer | 0 | 1949 |
| Mr. Tetsu Takayama | Executive MD & Director | 0 | 1961 |
| Hiroshi Noake | GM of Pharmaceutical Sales Headquarters & Director | 0 | 1964 |
| Keiji Miyazawa | GM of Research Division & Director | 0 | 1967 |
| Mr. Yasuo Takehana | President, Chief Operating Officer & Director | 0 | 1960 |
| Mr. Takahide Kitahara | GM of Financial Management Department, MD & Director | 0 | 1962 |
| Mr. Yoshio Furihata | Senior Advisor & Director | 0 | 1962 |
| Mr. Keiji Fukushima | Executive Vice President & Director | 0 | 1956 |
Kissei Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products primarily in Japan. It offers Urief and Urief OD tablets for the treatment of dysuria; Glufast, Glubes, and Marizev tablets for type 2 diabetes; Darbepoetin Alfa BS and Epoetin Alfa BS injections for the treatment of renal anemia; Beova tablets for overactive bladder treatment; P-TOL chewable tablets for treating hyperphosphatemia; and Minirin Melt OD tablets for nocturia due to nocturnal polyuria in males, central diabetes insipidus, and nocturnal enuresis resulted from decrease of urine osmolality. The company's products in pipeline include KPS-0373 that has completed Phase III clinical trial to treat spinocerebellar ataxia; CCX168, which has completed Phase III clinical trial for the treatment of microscopic polyangiitis and granulomatosis with polyangiitis; AJM300, which is in Phase III clinical trial to treat ulcerative colitis; R788 that is in Phase III clinical trial to treat chronic idiopathic thrombocytopenic purpura; and MR13A9, which is in Phase III clinical trial to treat uremic pruritus in dialysis patients. It is also developing KLH-2109 for treating endometriosis and uterine fibroids; KDT-3594 for the treatment of Parkinson's disease; Silodosin for dysuria associated with benign prostatic hyperplasia; Mitiglinide for type 2 diabetes mellitus; and Bedoradrine for the treatment of acute exacerbation of asthma. In addition, it develops and sells protein controlled and energy supply foods; and purchases and sells related materials, as well as offers system development and information processing, construction contracting, equipment and facility management, and information gathering and development support services. The company was formerly known as Kissei Yakuhin Kogyo Co., Ltd. and changed its name to Kissei Pharmaceutical Co., Ltd. in October 1964. The company was founded in 1946 and is headquartered in Matsumoto, Japan.
